Abstract
Vaccines have been considered in treating many CNS degenerative disorders, including Alzheimers disease (AD), Parkinsons disease (PD), Huntingtons disease (HD), epilepsy, multiple sclerosis (MS), spinal cord injury (SCI), and stroke. DNA vaccines have emerged as novel therapeutic agents because of the simplicity of their generation and application. Myelin components such as NOGO, MAG and OMGP are known to trigger demyelinating autoimmunity and to prevent axonal regeneration. For these reasons DNA vaccines encoding NOGO, MAG and OMGP, and fragments thereof, make them suitable vehicles for treatment of SCIs and MS. We need to obtain a deeper understanding of the immunologic mechanisms underlying the neuroprotective immunity to optimize the design of DNA vaccines for their use in clinical setting. In this review, we discuss recent findings suggesting that DNA vaccines hold a promising future for the treatment of axonal degeneration and demyelination.
Keywords: DNA vaccine, NOGO, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMGP), regeneration, spinal cord injury, multiple sclerosis, autoimmunity
Current Pharmaceutical Design
Title: DNA Vaccine and the CNS Axonal Regeneration
Volume: 13 Issue: 24
Author(s): Du-yu Nie, Gang Xu, Sohail Ahmed and Zhi-cheng Xiao
Affiliation:
Keywords: DNA vaccine, NOGO, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMGP), regeneration, spinal cord injury, multiple sclerosis, autoimmunity
Abstract: Vaccines have been considered in treating many CNS degenerative disorders, including Alzheimers disease (AD), Parkinsons disease (PD), Huntingtons disease (HD), epilepsy, multiple sclerosis (MS), spinal cord injury (SCI), and stroke. DNA vaccines have emerged as novel therapeutic agents because of the simplicity of their generation and application. Myelin components such as NOGO, MAG and OMGP are known to trigger demyelinating autoimmunity and to prevent axonal regeneration. For these reasons DNA vaccines encoding NOGO, MAG and OMGP, and fragments thereof, make them suitable vehicles for treatment of SCIs and MS. We need to obtain a deeper understanding of the immunologic mechanisms underlying the neuroprotective immunity to optimize the design of DNA vaccines for their use in clinical setting. In this review, we discuss recent findings suggesting that DNA vaccines hold a promising future for the treatment of axonal degeneration and demyelination.
Export Options
About this article
Cite this article as:
Du-yu Nie , Gang Xu , Sohail Ahmed and Zhi-cheng Xiao , DNA Vaccine and the CNS Axonal Regeneration, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368567
DOI https://dx.doi.org/10.2174/138161207781368567 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease
Current Neuropharmacology HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Expression and Function of Cytochrome P450 in Brain Drug Metabolism
Current Drug Metabolism Decreased ERp57 Expression in WAG/Rij Rats Thalamus and Cortex: Possible Correlation with Absence Epilepsy
Protein & Peptide Letters Editorial [Hot Topic: Monotherapy to Polytherapy: Antiepileptic Drug Conversions Through the Spectrum of Epilepsy Care (Guest Editor: Erik K. St. Louis)]
Current Neuropharmacology The Role of Inflammation in Epilepsy
Current Pediatric Reviews Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Aquaporins and Glia
Current Neuropharmacology Reverse Iontophoretic Extraction of Gabapentin: A Mechanistic Study
Current Drug Delivery Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews The Therapeutic Role of Electroencephalography in Deep Brain Stimulation in Intractable Epilepsy: A Recent Perspective
Recent Patents and Topics on Imaging (Discontinued) Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research Effect of the Surfactant and Liquid Lipid Type in the Physico-chemical Characteristics of Beeswax-based Nanostructured Lipid Carrier (NLC) of Metformin
Pharmaceutical Nanotechnology Preclinical Profile of Bacopasides From Bacopa monnieri (BM) As An Emerging Class of Therapeutics for Management of Chronic Pains
Current Medicinal Chemistry Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience